FIELD: medicine.
SUBSTANCE: effective amount of a chemotherapeutic agent and anti-VEGF antibodies (bevacizumab), wherein the agent represents either (a) capecitabine, (b) docetaxel or Abraxane, (c) or antracycline, and wherein the anti-VEGF antibody is administered at 15 mg/kg. No other chemotherapeutic agent has been administered into the individual for treating local recurrent or metastatic breast cancer, and/or the above individual has not undergone adjuvant pre-chemotherapy accompanying a recurrence for 12 months or less after the last dose administered. There are also presented the anti-VEGF antibody, using the anti-VEGF antibody and kits containing the anti-VEGF antibody in a combination with the chemotherapeutic agent for treating metastatic breast cancer.
EFFECT: prolonged individual's lifespan with no disease progression.
40 cl, 6 dwg, 5 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-ANGIOGENESIS THERAPY FOR TREATING PREVIOUSLY TREATED BREAST CANCER | 2010 |
|
RU2576027C2 |
| ANTIBODIES AGAINST PD-1 FOR TREATMENT OF LUNG CANCER | 2018 |
|
RU2771759C2 |
| COMBINATIONS AND METHODS FOR ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY | 2013 |
|
RU2673805C2 |
| COMPOSITIONS AND METHODS OF TREATING AND DIAGNOSING CANCER-RESISTANT CANCER | 2015 |
|
RU2710735C2 |
| VEGF POLYMORPHISM AND ANTIANGIOGENESIS THERAPY | 2013 |
|
RU2635525C2 |
| TREATMENT WITH ANTIBODIES AGAINST VEGF | 2004 |
|
RU2519669C2 |
| METHODS OF DIAGNOSIS AND COMPOSITION FOR CANCER TREATMENT | 2013 |
|
RU2666627C2 |
| COMBINED THERAPY FOR TREATING GLIOBLASTOMA | 2014 |
|
RU2692075C2 |
| VEGF POLYMORPHISM AND ANTIANGIOGENESIS THERAPY | 2008 |
|
RU2482491C2 |
| BIOLOGICAL MARKERS FOR IDENTIFYING PATIENTS FOR TREATMENT WITH VEGF ANTAGONISTS | 2013 |
|
RU2659173C2 |
